This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| MRC Prion Unit | |
|---|---|
| Name | MRC Prion Unit |
| Type | Research institute |
| Location | London |
| Parent organization | Medical Research Council |
| Established | 1994 |
| Focus | Prion diseases, neurodegeneration |
MRC Prion Unit The MRC Prion Unit is a London-based biomedical research centre specializing in prion diseases and protein misfolding disorders. It combines laboratory research, clinical diagnosis, and translational efforts, interacting with institutions such as University College London, University of Cambridge, St George's, University of London, National Health Service (England), and international partners like Centers for Disease Control and Prevention and World Health Organization. The Unit has contributed to understanding Creutzfeldt–Jakob disease, variant Creutzfeldt–Jakob disease, and links between prion biology and conditions studied at Massachusetts Institute of Technology, Harvard University, and National Institutes of Health.
The Unit was founded under the Medical Research Council (United Kingdom) during the 1990s amid the public health response to Bovine spongiform encephalopathy and variant Creutzfeldt–Jakob disease concerns that followed the United Kingdom bovine spongiform encephalopathy outbreak. Early collaborations involved investigators from Imperial College London, Guy's and St Thomas' NHS Foundation Trust, and the Wellcome Trust; policy links included the Department of Health and Social Care and advisory roles with the Spongiform Encephalopathy Advisory Committee. Leaders at the Unit engaged with clinicians from Great Ormond Street Hospital, Addenbrooke's Hospital, and researchers who had trained at University of Oxford, King's College London, and University of Edinburgh. Over time the Unit integrated methods and insights from groups at Max Planck Institute for Biophysical Chemistry, Pasteur Institute, and Karolinska Institute.
Research themes span molecular mechanisms of prion protein misfolding, transmission dynamics of prions, and overlaps with proteinopathies such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. Projects examine structural biology using techniques from teams at European Molecular Biology Laboratory, Diamond Light Source, and European Synchrotron Radiation Facility, and apply cryo-EM approaches developed at MRC Laboratory of Molecular Biology. Genetic studies connect to cohorts studied at Wellcome Sanger Institute and UK Biobank, while epidemiology interfaces with datasets from Public Health England and analyses akin to work by Johns Hopkins University and London School of Hygiene & Tropical Medicine. Therapeutic efforts leverage small-molecule screening strategies pioneered at GlaxoSmithKline, antibody platforms informed by AstraZeneca research, and antisense oligonucleotide approaches similar to those developed at Ionis Pharmaceuticals.
Laboratory capabilities include high-containment facilities compatible with biosafety practices promoted by Health and Safety Executive (United Kingdom) and specialized neuropathology suites linked to National Prion Clinic clinicians. Structural studies utilize equipment shared with Francis Crick Institute and imaging platforms used by King's College London Dental Institute. The Unit partners with international centers including Mayo Clinic, University of Toronto, University of California, San Francisco, and McGill University; it participates in consortia with European Centre for Disease Prevention and Control and engages with industry partners such as Pfizer and Roche for translational pipelines. Training collaborations include fellowships with Royal Society, Marie Skłodowska-Curie Actions, and exchanges with Cold Spring Harbor Laboratory.
Clinical case ascertainment and diagnostic assays are provided in coordination with the National Prion Clinic and neuropathology services at hospitals like Charing Cross Hospital and Addenbrooke's Hospital. Diagnostic techniques integrate RT-QuIC assays comparable to methods from University of Zurich groups, MRI protocols harmonized with standards from American College of Radiology, and genetic testing pipelines aligned with Genetics Society recommendations. The Unit contributes to surveillance networks including collaborations with European Creutzfeldt-Jakob Disease Surveillance Network and reporting frameworks interfacing with World Health Organization guidance.
Primary funding streams include awards from the Medical Research Council (United Kingdom), research grants from the Wellcome Trust, translational partnerships with Innovate UK, and competitive funding from bodies such as European Research Council and National Institute for Health Research. Governance involves oversight from advisory boards drawing members with appointments at University College London Hospitals NHS Foundation Trust, the Francis Crick Institute, and policy liaisons with the Department of Health and Social Care. The Unit complies with regulatory frameworks set by Human Tissue Authority and ethical oversight echoing Health Research Authority procedures.
Staff and alumni include clinicians and scientists with affiliations across institutions such as University of Cambridge, MRC Laboratory of Molecular Biology, University College London, London School of Hygiene & Tropical Medicine, King's College London, Imperial College London, Addenbrooke's Hospital, St Mary's Hospital, London, and international appointments at Harvard Medical School, Johns Hopkins University School of Medicine, and Karolinska Institutet. Fellows have held awards from Royal Society, Wellcome Trust Fellowship, European Research Council Starting Grant, and fellowships at Gulbenkian Foundation. Visiting investigators have come from Pasteur Institute, Max Planck Society, and Cold Spring Harbor Laboratory.
The Unit advanced diagnostics and understanding of transmissible spongiform encephalopathies, influencing public health responses to Bovine spongiform encephalopathy and informing policy during episodes linked to variant Creutzfeldt–Jakob disease. Scientific outputs have shaped structural models of prion protein conformers, contributed to RT-QuIC assay development parallel to work at University of California, San Diego and University of Zurich, and fostered therapeutic exploration influenced by research at Ionis Pharmaceuticals and antibody discovery paradigms used by Genentech. The Unit's integration of clinical, molecular, and epidemiological expertise continues to intersect with research on Alzheimer's disease and Parkinson's disease at institutes like MRC Cognition and Brain Sciences Unit and contributes to international surveillance coordinated with World Health Organization and European Centre for Disease Prevention and Control.
Category:Medical research institutes in the United Kingdom